News - MYD88 L265P + CD79B mutation

11ms

Diagnostic methods for primary vitreoretinal lymphoma: A systematic review. (PubMed, Surv Ophthalmol)

Overall, our systematic review found that an IL-10/IL-6 ratio greater or equal to one may provide the highest sensitivity in identifying patients with PVRL. Future studies are needed to employ multiple diagnostic tools to aid in the detection of PVRL to further establish nuanced guidelines when determining the optimal diagnostic tool to use in diverse patient populations.

11 months ago

Review • Journal

MYD88 (MYD88 Innate Immune Signal Transduction Adaptor) • IGH (Immunoglobulin Heavy Locus) • CD79B (CD79b Molecule) • IL10 (Interleukin 10) • IL6R (Interleukin 6 receptor)

MYD88 L265P • CD79B mutation • CD79B mutation • MYD88 L265P + CD79B mutation

1year

Plasma Circulating Tumor DNA (ctDNA) as an Alternative to Tissue DNA for Genotyping of DLBCL: Results from the POLARIX Study (ASH 2023)

Introduction: In the POLARIX study (NCT03274492), polatuzumab vedotin in combination with rituximab plus cyclophosphamide, doxorubicin, and prednisone (Pola-R-CHP) demonstrated prolonged progression-free survival (PFS) versus rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in patients with previously untreated diffuse large B-cell lymphoma (DLBCL; Tilly et al. Our analyses demonstrated that the mutation landscape of ctDNA in DLBCL characterized by the AVENIO ctDNA NHL assay resembles that of tumor tissue determined by WES. Patients with molecular subtypes defined by WES or ctDNA had similar PFS outcomes. Overall, these findings support the use of plasma ctDNA as an alternative to tumor tissue for the genotyping of DLBCL.

1 year ago

IO biomarker • Circulating tumor DNA

TP53 (Tumor protein P53) • BCL2 (B-cell CLL/lymphoma 2) • NOTCH1 (Notch 1) • BCL6 (B-cell CLL/lymphoma 6) • TET2 (Tet Methylcytosine Dioxygenase 2) • KMT2D (Lysine Methyltransferase 2D) • CD79B (CD79b Molecule) • NOTCH2 (Notch 2) • TNFAIP3 (TNF Alpha Induced Protein 3) • DCHS1 (Dachsous Cadherin-Related 1) • TP53BP1 (Tumor Protein P53 Binding Protein 1)

TP53 mutation • NOTCH1 mutation • TET2 mutation • KMT2D mutation • EZH2 mutation • MYD88 L265P • CD79B mutation • BCL6 rearrangement • CD79B mutation • NOTCH2 mutation • BCL2 rearrangement • BCL6 translocation • MYD88 L265P + CD79B mutation • TP53BP1 mutation • BCL2 translocation

Rituxan (rituximab) • doxorubicin hydrochloride • cyclophosphamide • vincristine • prednisone • Polivy (polatuzumab vedotin-piiq)

over1year

Comparative analysis of clinicopathologic features and tumor immune-microenvironment of primary diffuse large B cell lymphoma of the central nervous system according to molecular classification (AACR 2023)

This is the first reporting molecular classification and their clinical significance in PCNS-DLBCL of Asian population. MCD subtype was prevalent but has no prognostic power in PCNS-DLBCL. Further larger study is needed.

over 1 year ago

Clinical • PD(L)-1 Biomarker • IO biomarker

PD-L1 (Programmed death ligand 1) • TP53 (Tumor protein P53) • CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • CD8 (cluster of differentiation 8) • PD-1 (Programmed cell death 1) • CD79B (CD79b Molecule) • CD163 (CD163 Molecule) • BCL7A (BAF Chromatin Remodeling Complex Subunit BCL7A) • CD68 (CD68 Molecule) • CD79A (CD79a Molecule) • FOXP3 (Forkhead Box P3) • MVP (Major Vault Protein)

PD-L1 expression • TP53 mutation • LDH elevation • CDKN2A deletion • CDKN2A mutation • MYD88 L265P • PD-1 expression • CD79B mutation • CD79B mutation • CD79A mutation • BCL7A mutation • MYD88 L265P + CD79B mutation • CD79A mutation + CD79B mutation

2years

Intravascular Large B-Cell Lymphoma Genomic Profile Is Characterized by Alterations in Genes Regulating NF-κB and Immune Checkpoints. (PubMed, Am J Surg Pathol)

Our results confirm the relevance of mutations in B-cell receptor/nuclear factor-κB signaling and immune escape pathways in IVLBCL and identify novel driver alterations. The similar mutational profile in tumors with extravascular dissemination suggests that these cases may also be considered in the spectrum of IVLBCL.

2 years ago

Journal • PD(L)-1 Biomarker • IO biomarker

PD-L1 (Programmed death ligand 1) • ETV6 (ETS Variant Transcription Factor 6) • CD79B (CD79b Molecule) • NOTCH2 (Notch 2) • GNA13 (G Protein Subunit Alpha 13) • PIM1 (Pim-1 Proto-Oncogene) • CCND3 (Cyclin D3) • IRF4 (Interferon regulatory factor 4) • BTG2 (BTG Anti-Proliferation Factor 2)

PD-L1 expression • MYD88 L265P • CD79B mutation • CD79B mutation • NOTCH2 mutation • PIM1 mutation • MYD88 L265P + CD79B mutation

over3years

The alternative RelB NF-κB subunit is a novel critical player in diffuse large B-cell lymphoma. (PubMed, Blood)

Functional studies revealed that RelB confers DLBCL cell resistance to DNA-damage induced apoptosis in response to doxorubicin, a genotoxic agent used in front-line treatment for DLBCL. We also show that RelB positivity is associated with high expression of cIAP2. Altogether, RelB activation can be used to refine the prognostic stratification of DLBCL and may contribute to subvert the therapeutic DNA damage response in a segment of DLBCL patients.

over 3 years ago

Journal

CD79B (CD79b Molecule) • BIRC3 (Baculoviral IAP repeat containing 3)

MYD88 L265P • CD79B mutation • CD79B mutation • MYD88 L265P + CD79B mutation

doxorubicin hydrochloride